As the COVID-19 pandemic intensifies, IDF partner Medicines Patent Pool (MPP) is mobilizing its network to encourage innovators developing new or re-purposed therapies to negotiate public health licensing agreements with MPP to allow for broader access to their know-how and intellectual property.
The initiative “Mobilising the power of collective action against COVID-19 – An Open Pledge from Global Manufacturers of Generic Medicines” has been signed by 18 leading generic manufacturing companies who work with MPP.
IDF supports this pledge as it aligns with our ongoing efforts to push for equitable access to COVID-19 diagnosis, vaccines and treatments. These are particularly important for people living with diabetes and other NCDs.
Image credit: © Medicines Patent Pool (MPP)